ID   SUP-M2-CR03
AC   CVCL_V405
SY   SUPM2CR03
DR   Cosmic; 1849570
DR   Wikidata; Q54970878
RX   PubMed=23239810;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (from parent cell line).
CC   Derived from site: In situ; Cerebrospinal fluid; UBERON=UBERON_0001359.
DI   NCIt; C37193; Anaplastic large cell lymphoma, ALK-positive
DI   ORDO; Orphanet_300895; ALK-positive anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2209 ! SUP-M2
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 29-06-23; Version: 14
//
RX   PubMed=23239810; DOI=10.1158/1541-7786.MCR-12-0569;
RA   Ceccon M., Mologni L., Bisson W.H., Scapozza L.,
RA   Gambacorti-Passerini C.;
RT   "Crizotinib-resistant NPM-ALK mutants confer differential sensitivity
RT   to unrelated Alk inhibitors.";
RL   Mol. Cancer Res. 11:122-132(2013).
//